Overall, these data indicate that an increased expression of ATP1A1 and ATP1B1 in women carrying ERα-positive tumors does not indicate the possibility to use OU or other CGs and suggests that OU or other CGs administration could be an exploitable option in ERα-positive BC in those women expressing high levels of ATP1B3. The gene discussed is ESR1; the disease is breast cancer.